PMN
MaterialsProMIS Neurosciences Inc
$11.00-0.06 (-0.50%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PMN Today?
No stock-specific AI insight has been generated for PMN yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$99M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume28K
Avg Volume (10D)—
Shares Outstanding9.0M
PMN News
20 articles- Phoenix Mecano's (VTX:PMN) Conservative Accounting Might Explain Soft EarningsYahoo Finance·Apr 30, 2026
- ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor ConferenceYahoo Finance·Apr 13, 2026
- ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsYahoo Finance·Mar 25, 2026
- ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)Yahoo Finance·Mar 18, 2026
- Five US Stocks See Over $185M in Insider Buying, with Soho House and WR Berkley Leading the Pack247 Wall St·Feb 9, 2026
- ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- ProMIS Neurosciences Announces Up to $175 Million Private Placement FinancingYahoo Finance·Jan 30, 2026
- An Intrinsic Calculation For Phoenix Mecano AG (VTX:PMN) Suggests It's 44% UndervaluedYahoo Finance·Jan 18, 2026
- Phoenix Mecano (VTX:PMN) shareholders have earned a 15% CAGR over the last three yearsYahoo Finance·Jan 1, 2026
- ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s DiseaseYahoo Finance·Dec 18, 2025
- Is Phoenix Mecano AG's (VTX:PMN) Latest Stock Performance Being Led By Its Strong Fundamentals?Yahoo Finance·Dec 12, 2025
- ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA RiskYahoo Finance·Dec 10, 2025
- ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310Yahoo Finance·Dec 1, 2025
- ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare ConferenceYahoo Finance·Dec 1, 2025
- ProMIS Neurosciences Announces Reverse Stock SplitYahoo Finance·Nov 24, 2025
- Can ProMIS Neurosciences (NASDAQ:PMN) Afford To Invest In Growth?Yahoo Finance·Nov 15, 2025
- ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate HighlightsYahoo Finance·Nov 12, 2025
- Phoenix Mecano (VTX:PMN) Might Have The Makings Of A Multi-BaggerYahoo Finance·Nov 7, 2025
- ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceYahoo Finance·Nov 3, 2025
- ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge GroupYahoo Finance·Oct 22, 2025
All 20 articles loaded
Price Data
Open$11.15
Previous Close$11.06
Day High$11.23
Day Low$11.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$99M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume28K
Avg Volume (10D)—
Shares Outstanding9.0M
About ProMIS Neurosciences Inc
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—